Clinical trials: Breast Cancer/ Metastatic Breast Cancer
Breast Cancer
FDHT PET and Bicalutamide in Metastatic Breast Cancer
Rationale: The purpose is to evaluate whether non-invasive in vivo imaging of androgen receptor (AR) presence in metastatic breast cancer patients by means of 18F-fluoro-dihydrotestosterone positron emission tomography (FDHT-PET)…
- Trial name
- NCT02697032
- Testing
- Bicalutamide, FDHT PET
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- University Medical Center Groningen
Oligometastatic Breast Carcinoma, Breast Cancer
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer.
- Conditions
- Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma
- Trial name
- NCT05534438
- Testing
- Stereotactic body radiotherapy
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced or Metastatic Solid Tumors, Breast Cancer
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
- Trial name
- NCT06257758
- Testing
- VIO-01
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Valerio Therapeutics
Breast Carcinoma, Male Breast Carcinoma
Access to Genetic Testing in Underserved Patients With Cancer
This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider.
- Conditions
- Breast Carcinoma, Male Breast Carcinoma, Malignant Solid Neoplasm, Metastatic Prostate Carcinoma
- Trial name
- NCT06422455
- Testing
- Best Practice, Educational Intervention, Electronic Health Record Review
- Where
- 2 sites in United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Southern California
HER2-positive Breast Cancer
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
Heterogeneity of 18F-fluorodeoxyglucose (FDG) uptake is a promising marker for predicting response to treatment. This study aimed to evaluate the ability of pretreatment positron emission tomography/computed tomography (PET/CT)…
- Trial name
- NCT04756921
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Biyun Wang, MD
Breast Cancer
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
The goals of this clinical research study are to learn the tolerable and effective doses of the drug MK-0646 that can be given in combination with Sprycel (dasatinib) and Faslodex (fulvestrant) to patients with hormone…
- Trial name
- NCT00903006
- Testing
- Fulvestrant, MK-0646, Dasatinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced, Metastatic Breast Cancer
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of Letrozole SIE (injectable) compared to Femara® (oral tablet), both given together with ribociclib, for the first-line treatment of postmenopausal women with…
- Trial name
- SIE-3 (NCT07340658)
- Volunteers
- 300 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
HER2-positive Breast Cancer, Male Breast Cancer
Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
RATIONALE : Laboratory-treated T cells may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor…
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01219907
- Testing
- HER-2/neu peptide vaccine, cyclophosphamide, ex vivo-expanded HER2-specific T cells
- Where
- United States
- Sponsor
- University of Washington
Breast Cancer
A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
JCOG1919E (AMBITION) is a randomized, open-label, phase 3 trial to evaluate efficacy and safety of bevacizumab and paclitaxel in combination with atezolizumab comparing to bevacizumab and paclitaxel in patients with HR-positive…
- Trial name
- AMBITION (NCT04732598)
- Testing
- Paclitaxel + bevacizumab therapy, Paclitaxel + bevacizumab + atezolizumab
- Where
- Japan
- Volunteers
- 281 people
- Sponsor
- Japanese Foundation for Cancer Research
Breast Cancer
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Dose Escalation part of the study: To estimate the MTD(s) and/ or RP2D of LEE011 in combination with everolimus + exemestane, and LEE011 in combination with exemestane, and to characterize the safety and tolerability of the…
- Trial name
- NCT01857193
- Testing
- ribociclib (LEE011), Exemestane, Everolimus (RAD001)
- Where
- 13 sites in United States, Belgium and 3 more
- Volunteers
- 132 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Breast Cancer
A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors
The goal of this clinical trial is to learn about the effect of food on absorption of oral Paclitaxel when co- administered with Encequidar tablets in adult patients with tumours.
- Trial name
- NCT07580833
- Testing
- Oral Paclitaxel in combination with Encequidar tablet
- Volunteers
- 46 people
- Sponsor
- Health Hope Pharma
Breast Cancer
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
- Trial name
- NCT07062965
- Testing
- PF-07248144, Fulvestrant, Everolimus
- Where
- 433 sites in United States, Argentina and 29 more
- Volunteers
- 400 people
- Sponsor
- Pfizer
Breast Cancer
C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
The purpose of this research project is to create images of where and how the amino acid (the building blocks of proteins)Tryptophan is processed in normal and abnormal tissue in the patient's body.
- Trial name
- NCT01302821
- Testing
- Adenovirus-p53 transduced dendritic cell vaccine, 1-methyl-D-tryptophan, Carbon C 11 alpha-methyltryptophan
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Recurrent Breast Cancer, Stage IV Breast Cancer
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer
This phase II trial is studying how well giving capecitabine together with tipifarnib works in treating women with taxane-resistant metastatic breast cancer.
- Trial name
- NCT00077363
- Testing
- tipifarnib, capecitabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Mammary Neoplasms, Human
The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.
This study was a single-arm, open-label, phase II study of breast cancer patients with brain metastases. Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and…
- Trial name
- NCT05781633
- Testing
- eutidrone etoposide bevacizumab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Breast Cancer
A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer
This study will use proteomic and genomic profiling to analyze tumor tissue to see if treatment selected by this analysis will benefit patients.
- Trial name
- SO2 (NCT01919749)
- Testing
- treated recommended
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Translational Drug Development
Metastatic Breast Cancer
A Confirmation Study of Eribulin in Combination With Capecitabine
This is a Phase 1b/2, multi-center, open-label, dose escalation (in 2 different dosing schedules [1 and 2]) and dose-confirmation study of eribulin administered in combination with capecitabine.
- Trial name
- NCT01323530
- Testing
- Eribulin mesylate, Capecitabine
- Where
- 10 sites in Bulgaria, Russia and 1 more
- Volunteers
- 76 people
- Sponsor
- Eisai Limited
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.